Concussions Market

• The concussion market is expected to continue growing steadily during the forecast period (2024-2034). This growth is mainly driven by improvements in diagnostic methods, increased awareness of the condition, and more number of reported cases.
• The number of concussion cases is increasing due to several factors such as falls, accidents, and sports-related activities, specifically soccer and football, among others.
• Currently, there are no established guidelines for pharmaceutical therapy in the treatment of post-concussion syndrome (PCS) and mild traumatic brain injury (mTBI) symptoms.
• The growing number of concussions and mild traumatic brain injuries (mTBI) with the lack of evidence-based treatment options is a continuous health concern for sports medicine providers.
• To drive the concussion market in future years, several companies such as Oxeia Biopharmaceuticals, American CryoStem Corporation, and others are developing their assets in the mid-late stage of development. With the expected approval of these therapies during the forecast period [2024–2034], the overall therapeutic market of concussion is likely to witness a rise at a significant CAGR.
• Among the emerging therapies one of the emerging drugs OXE-103 under the developmental pipeline of Oxeia Biopharmaceuticals is anticipated to be launched during the forecast period (2024-2034).

DelveInsight’s comprehensive report titled “Concussion Market Insights, Epidemiology, and Market Forecast – 2034” offers a detailed analysis of concussion. The report presents historical and projected epidemiological data covering Total Incident Cases of Concussion further segmented by Gender, Age, and Causes. In addition to epidemiology, the market report encompasses various aspects related to the patient population. These aspects include the diagnosis process, prescription patterns, physician perspectives, market accessibility, treatment options, and prospective developments in the market across seven major markets: the United States, EU4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan, spanning from 2020 to 2034.

The report analyzes the existing treatment practices and unmet medical requirements in concussion. It evaluates the market potential and identifies potential business prospects for enhancing therapies or interventions. This valuable information enables stakeholders to make well-informed decisions regarding product development and strategic planning for the market.

Concussion Overview

According to the Centers for Disease Control and Prevention, a concussion is a type of traumatic brain injury (TBI) caused by a bump, blow, or jolt to the head or by a hit to the body that causes the head and brain to move rapidly back and forth. This injury results in temporary loss of normal brain function. Medically, it is defined as a clinical syndrome characterized by immediate and transient alteration in brain function, including alteration of mental status or level of consciousness that results from mechanical force or trauma.

A concussion is generally caused by a direct blow to the head, but it can also occur from rapid acceleration and deceleration of the brain within the skull (e.g., whiplash in a car accident). The impact results in chemical changes and damage to brain cells. Some causes of concussion include injuries during sports, falls, car accidents, violence, blast injuries, or other occupational hazards. Concussion may or may not include loss of consciousness (blackout). The loss of consciousness is often brief and is normally followed by a rapid and complete recovery.

Common symptoms associated with concussion include confusion, headache, vision disturbances (double or blurry vision), dizziness or imbalance, nausea or vomiting, memory loss, ringing ears, difficulty concentrating, sensitivity to light, loss of smell or taste, and trouble falling asleep, among others.

A concussion can affect memory, judgment, reflexes, speech, balance, and muscle coordination. People with concussions often report a brief period of amnesia or forgetfulness, where they cannot remember what happened immediately before or after the injury.

Concussion Diagnosis and Treatment Algorithm

Diagnosis of concussion typically involves a thorough evaluation by a medical professional, such as a doctor or a neuropsychologist. This may include a physical examination, neurological assessments, and cognitive tests. Imaging tests like CT scans or MRIs are usually normal in cases of concussion, as they primarily detect structural damage.

The primary treatment for a concussion is rest, both physical and cognitive. This allows the brain to heal without additional strain. In some cases, a healthcare provider may recommend a gradual return to normal activities based on the progression of symptoms. It's important to follow medical advice and not rush the recovery process to prevent worsening symptoms. Concussion treatment aims to address the physical, cognitive, emotional, and psychological aspects of the injury.

Over-the-counter pain relievers like acetaminophen (Tylenol) can help manage headaches associated with concussions. Non-steroidal anti-inflammatory drugs (NSAIDs) like ibuprofen may also be used, but it's important to consult a healthcare professional before taking any medication after a concussion. These medications can mask symptoms and thin the blood, which may increase the risk of bleeding.

Osteopathic cranial manipulative medicine (OCMM) is a non-pharmacologic method that has recently been evaluated as a potential alternative treatment. OCMM is based on the idea that the anatomy of the cranium reflects the human body as a whole.

Hyperbaric oxygen therapy (HBOT) has been researched as a treatment method for persistent post-concussive symptoms (PPCS). HBOT involves a chamber that is slowly pressurized to 1.5–3 times higher than normal air pressure with pure oxygen

Concussion Epidemiology

The epidemiology section of the concussion market report offers information on the patient populations, including historical and projected trends for each of the seven major markets. Examining key opinion leader views from physicians or clinical experts can assist in identifying the reasons behind historical and projected trends. The diagnosed patient pool, their trends, and the underlying assumptions are all included in this section of the report.

This section also presents the data with relevant tables and graphs, offering a clear and concise view of the Incidence of concussions. Additionally, the report discloses the assumptions made during the analysis, ensuring data interpretation and presentation transparency. This epidemiological data is valuable for understanding the disease burden and its impact on the patient population across various regions.

Key Findings

• In the concussion analysis, it was revealed that an estimated 1.7 to 3 million concussions occur annually due to sports and recreational activities. Of these incidents, approximately 300,000 are attributed to football-related activities.
• The analysis indicated that girls' soccer ranks second in the frequency of concussions among all high school sports, with girls' basketball following closely behind in third place. Moreover, it was noted that two out of every ten high school athletes who participate in contact sports experience concussions.
• In the analysis, it was determined that approximately 3.9% of children aged 17 years and under in the US had received a diagnosis of a concussion or brain injury from a healthcare provider at some point.
• The analysis noted that approximately 1 in 100 children aged 9 and 10 sustain a concussion within a year in the US.
• During the analysis, it was found that the majority of concussions occurred in organized sports settings, accounting for 53.3% of incidents. Additionally, injuries within school environments constituted 16.5% of cases, followed by recreational settings at 6.7%, motor vehicle collisions at 6.6%, home environments at 5.5%, and other miscellaneous settings at 11.3%. Among specific subcategories, soccer (12.9%), school physical education (PE) classes (10.6%), and football (9.8%) were identified as the settings with the highest incidence rates of concussion.
• It's anticipated that the epidemiology of concussion will undergo changes throughout the forecast period from 2024 to 2034.

Concussion Market Outlook

The concussion therapeutics market is further expected to increase by the major drivers, such as the rising Incident population, technological advancements, and upcoming therapies in the forecast period [2024–2034].

• In October 2021, Oxeia Biopharmaceuticals initiated a Phase II clinical trial of OXE-103 for the treatment of mild traumatic brain injury (TBI).
• With ongoing research and continued dedication, the future holds hope for even more effective treatments and, ultimately, a cure for this challenging condition. According to DelveInsight, the Concussion market in the 7MM is expected to change significantly during the study period 2020–2034.

Concussion Drug Chapters

Emerging Concussion Drugs

The concussion market is expected to experience gradual changes, mainly due to the limited availability of emerging therapies in this area. Key market players, including Oxeia Biopharmaceuticals, American CryoStem Corporation, and others have demonstrated a keen interest in this condition and are actively pursuing the development of potential treatments.

OXE-103: Oxeia Biopharmaceuticals

OXE103 is synthetic human ghrelin, an endogenous hormone. OXE103 freely crosses the blood-brain barrier and helps stabilize metabolic and energy brain dysfunction following a concussion. OXE103 uniquely targets the hippocampus region of the brain, an area important for cognition and memory. Treatment with OXE103 has been shown in numerous animal and laboratory studies to restore normal energy metabolism, increase appetite, and reduce the toxic effects of reactive oxygen species that form in low-energy states. Currently, the drug is in Phase II of clinical development for neurological healing and symptom management following mild TBI.

ATCell: American CryoStem Corporation

American CryoStem Corporation has developed a proprietary end-to-end Adipose Tissue Processing Platform consisting of the “Collection – Processing – Cryobanking – Return to Point-of-Care“– on demand, of adipose tissue and adipose-derived mesenchymal stems cells. The company received FDA clearance from the US FDA for its Investigational New Drug (IND) Phase I Clinical Trial “ATCell, a proprietary expanded autologous adipose-derived mesenchymal stem cell therapy for the treatment of Post-Concussion Syndrome (PCS). The purpose of the Phase I Clinical Trial is to evaluate the safety and efficacy of ATCell infusion therapy. Currently, the drug is in Phase I of clinical development according to clinicaltrials.gov.

Note: Detailed emerging therapies assessment will be provided in the final report…

Concussion Market Segmentation

DelveInsight’s ‘Concussion – Market Insights, Epidemiology, and Market Forecast – 2034’ report provides a detailed outlook of the current and future concussion market, segmented within countries, by therapies, and by classes. Further, the market of each region is then segmented by each therapy to provide a detailed view of the current and future market share of all therapies.

Concussion Market Size by Countries

The concussion market size is assessed separately for various countries, including the United States, EU4 (Germany, France, Italy, and Spain), the UK, and Japan. In 2023, the United States held a significant share of the overall 7MM (Seven Major Markets) concussion market, primarily attributed to the country's higher Incidence of the condition and the elevated cost of the available treatments. This dominance is projected to persist, especially with the potential early introduction of new products.

Country-wise Market Size Distribution of Concussion

Concussion Market Size by Therapies

Concussion Market Size by Therapies is categorized into current and emerging markets for the study period 2020–2034.

Market Share Distribution of Concussion by Therapies in 2034

Note: Detailed market segment assessment will be provided in the final report....

Concussion Drugs Uptake

This section focuses on the sales uptake of potential concussion drugs that have recently been launched or are anticipated to be launched in the concussion market between 2020 and 2034. It estimates the market penetration of concussion drugs for a given country, examining their impact within and across classes and segments. It also touches upon the financial and regulatory decisions contributing to the probability of success (PoS) of the drugs in the concussion market.

The emerging concussion therapies are analyzed based on various attributes such as safety and efficacy in randomized clinical trials, order of entry and other market dynamics, and the unmet need they fulfill in the concussion market.

Note: Detailed assessment of drug uptake and attribute analysis will be provided in the full report on concussion....

Concussion Market Access and Reimbursement

DelveInsight’s ‘Concussion – Market Insights, Epidemiology, and Market Forecast – 2034’ report provides a descriptive overview of the market access and reimbursement scenario of concussion.

This section includes a detailed analysis of the country-wise healthcare system for each therapy, enlightening the market access, reimbursement policies, and health technology assessments.

KOL Views

To keep up with current concussion market trends and fill gaps in secondary findings, we interview KOLs and SMEs’ working in the concussion domain. Their opinion helps understand and validate current and emerging therapies and treatment patterns or concussion market trends. This will support the clients in potential upcoming novel treatments by identifying the overall scenario of the market and the concussion unmet needs.

Concussion: KOL Insights

DelveInsight’s analysts connected with 50+ KOLs to gather insights; however, interviews were conducted with 15+ KOLs in the 7MM. These KOLs were from organizations, institutes, and hospitals, such as the American Association of Neurological Surgeons, the Brain Foundation, the Concussion Legacy Foundation, the Brain Injury Association of America, the Department of Family Medicine and Orthopedics, Department of Integrative Physiology, University of Colorado in the US, Seattle Children’s Research Institute in the US, FIFA Medical Centre of Excellence in Germany, Department of Trauma Surgery, University Medical Centre Regensburg in Germany, among others

“The increasing frequency of sport-related concussion and the emerging possible long-term health risks continue to raise concern in the health care community, in the general public, and to those who set public policy.”

“The annual incidence of approximately 1.2% of the population is the highest rate of concussion ever reported through sampling methods and may represent a closer estimate of the true picture of concussion.”

Note: Detailed assessment of KOL Views will be provided in the full report on concussion....

Competitive Intelligence Analysis

We conduct a Competitive and Market Intelligence analysis of the concussion Market, utilizing various Competitive Intelligence tools such as SWOT analysis and Market entry strategies. The inclusion of these analyses is contingent upon data availability, ensuring a comprehensive and well-informed assessment of the market landscape and competitive dynamics.

Concussion Pipeline Development Activities

The report offers an analysis of therapeutic candidates in Phase II and III stages and examines companies involved in developing targeted therapeutics for concussion. It provides valuable insights into the advancements and progress of potential treatments in clinical development for this condition.

Pipeline Development Activities

The report covers information on collaborations, acquisitions and mergers, licensing, patent details, and other information for emerging concussion therapies.

Concussion Report Insights

Concussion Patient Population

Therapeutic Approaches

Concussion Pipeline Analysis

Concussion Market Size and Trends

Concussion Market Opportunities

Impact of Upcoming Therapies

Concussion Report Key Strengths

• 11 Years Forecast
• The 7MM Coverage
• Concussion Epidemiology Segmentation
• Key Cross Competition
• Highly Analyzed Concussion Market
• Concussion Drugs Uptake

Concussion Report Assessment

• Concussion Current Treatment Practices
• Unmet Needs
• Concussion Pipeline Product Profiles
• Concussion Market Attractiveness

Key Questions

• How common is concussion?
• What are the key findings of concussion epidemiology across the 7MM, and which country will have the highest number of patients during the study period (2020–2034)?
• What are the currently available treatments for concussion?
• What is the disease risk, burden, and unmet needs of concussion?
• At what CAGR is the concussion market and its epidemiology is expected to grow in the 7MM during the forecast period (2024–2034)?
• How would the unmet needs impact the concussion market dynamics and subsequently influence the analysis of the related trends?
• What would be the forecasted patient pool of concussion in the 7MM covering the United States, EU4 (Germany, France, Italy, and Spain), the UK, and Japan?
• Among EU4 and the UK, which country will have the highest number of patients during the forecast period (2024–2034)?
• How many companies are currently developing therapies for the treatment of concussions?

Reasons to buy

• The report will help in developing business strategies by understanding the latest trends and changing treatment dynamics driving the concussion Market.
• Insights on patient burden/disease Incidence, evolution in diagnosis, and factors contributing to the change in the epidemiology of the disease during the forecast years
• To understand the existing market opportunity in varying geographies and the growth potential over the coming years.
• Distribution of historical and current patient share based on real-world prescription data along with reported sales of current treatment in the US, EU4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan.
• Identification of strong upcoming players in the market will help in devising strategies that will help in getting ahead of competitors.
• Detailed analysis and ranking of class-wise potential current and emerging therapies under the conjoint analysis section to provide visibility around leading classes.
• Highlights of Access and Reimbursement policies of approved therapies, barriers to accessibility of off-label expensive therapies, and patient assistance programs.
• To understand the perspective of Key Opinion Leaders around the accessibility, acceptability, and compliance-related challenges of existing treatment to overcome barriers in the future.
• Detailed insights on the unmet needs of the existing market so that the upcoming players can strengthen their development and launch strategy.